Trial Profile
Phase 3 Open-Label Extension Study to Evaluate the Safety, Tolerability and Activity of Oral Fampridine-SR in Patients With Multiple Sclerosis,
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 02 Mar 2012
Price :
$35
*
At a glance
- Drugs Fampridine (Primary)
- Indications Multiple sclerosis
- Focus Adverse reactions
- 31 Jan 2012 Primary endpoint changed as reported by ClinicalTrials.gov.
- 14 May 2011 New trial record